Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
This page aggregates historical and ongoing news coverage related to the ticker symbol LIFE, which historically represented aTyr Pharma, Inc. on the Nasdaq Capital Market. aTyr describes itself as a clinical stage biotechnology company developing first-in-class medicines from a proprietary tRNA synthetase platform, with a focus on fibrosis and inflammation. Company news has highlighted scientific progress, clinical milestones, and corporate developments tied to this strategy.
Readers can expect news items covering aTyr’s lead therapeutic candidate, efzofitimod, a biologic immunomodulator in clinical development for interstitial lung disease. Press releases have described key events such as Phase 3 EFZO-FIT™ trial updates in pulmonary sarcoidosis, Phase 2 EFZO-CONNECT™ enrollment in systemic sclerosis-related interstitial lung disease, and independent data and safety monitoring board reviews recommending continuation of the EFZO-FIT™ study without modification. Scientific conference presentations, including posters detailing efzofitimod’s mechanism of action through neuropilin-2 and its effects on myeloid cells, also feature prominently.
In addition to clinical and scientific updates, the news stream includes corporate communications such as quarterly results, pipeline summaries, and the announcement of the Nasdaq ticker change from LIFE to ATYR. These releases provide context on how aTyr is advancing its tRNA synthetase-based discovery platform, managing its clinical portfolio, and communicating with the investment community.
For investors, researchers, and clinicians following aTyr, the LIFE news archive offers a structured view of how the company’s programs have evolved over time. By reviewing these items, users can trace the development of efzofitimod in interstitial lung disease, observe the company’s engagement with scientific and investor conferences, and understand the rationale behind the transition from the LIFE ticker to ATYR. Bookmark this page to access a consolidated history of company announcements associated with the LIFE symbol.
aTyr Pharma, Inc. (Nasdaq: LIFE) has successfully completed enrollment in its Phase 2 clinical trial of ATYR1923, targeting COVID-19 patients with severe respiratory complications. The trial enrolled 32 patients, surpassing the initial goal of 30. Results are anticipated by the fourth quarter of 2020. ATYR1923 aims to address excessive inflammatory responses in the lungs, offering a potential treatment where few options exist. The study is a double-blind, placebo-controlled trial, evaluating safety and efficacy through key clinical outcomes over a 60-day follow-up period.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) announced participation in two virtual investor events this October. CEO Sanjay S. Shukla will engage in a Q&A webinar on October 12 at 12:00pm ET, part of the ROTH Capital Partners’ CEO Talk Series. CFO Jill M. Broadfoot will present a corporate overview at the BIO Investor Forum Digital from October 13-15. aTyr focuses on developing innovative medicines based on tRNA synthetases, particularly its clinical-stage candidate ATYR1923 for inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced a $20 million Common Stock Purchase Agreement with Aspire Capital on Sept. 14, 2020. The agreement allows Aspire Capital to purchase shares over a span of 30 months, with timing controlled by aTyr. This deal provides aTyr with flexible capital access to support its clinical programs, including ATYR1923 for pulmonary sarcoidosis and COVID-19 complications. Notably, aTyr retains the option to terminate the agreement without penalty. The funding aims to enhance its innovative therapies focused on immunological pathways.
aTyr Pharma (Nasdaq: LIFE) announced its participation in two key investor conferences in September 2020. Sanjay S. Shukla, M.D., President and CEO, will provide updates at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 10:30 a.m. ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:50 a.m. ET. Both events will be held virtually, and presentations will be available for replay on the company's website for 90 days post-event.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported its second quarter results, noting a positive shift in enrollment for the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis despite initial COVID-19 disruptions. A Phase 2 trial for ATYR1923 in COVID-19 patients with severe respiratory issues has commenced with promising initial safety results. Financially, total revenues reached $8.3 million for the first half of 2020, largely due to license agreements, while R&D expenses rose to $8.0 million driven by clinical activities. Cash reserves stood at $41.4 million as of June 30, 2020.
aTyr Pharma has announced that its partner, Kyorin Pharmaceutical, has initiated clinical development for ATYR1923 in Japan after receiving approval from the PMDA. The Phase 1 study will focus on safety, pharmacokinetics, and immunogenicity in healthy volunteers. aTyr received an $8 million upfront payment and could earn up to $167 million in milestone payments, along with tiered royalties on sales in Japan. aTyr is also enrolling a Phase 1b/2a trial for pulmonary sarcoidosis and a Phase 2 trial for COVID-19 patients experiencing severe respiratory issues.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced it will report its second quarter 2020 financial results and provide a corporate update on August 13, 2020, after market close. The company focuses on developing innovative medicines targeting novel immunological pathways, with its lead product ATYR1923 aimed at treating inflammatory lung diseases by binding to the neuropilin-2 receptor. The conference call is scheduled for the same day at 5:00 p.m. EDT.
aTyr Pharma (Nasdaq: LIFE) revealed new research linking Neuropilin receptors to SARS-CoV-2 infection, positioning its lead candidate, ATYR1923, as a potential therapeutic for COVID-19 related lung complications. Studies indicate that SARS-CoV-2 Spike protein binds to Neuropilin receptors, enhancing viral entry. ATYR1923, currently undergoing clinical trials for severe respiratory conditions, selectively modulates Neuropilin-2 to reduce inflammation. The research underscores the drug's potential role in combating SARS-CoV-2 infectivity and suggests broader applications in cancer and inflammatory diseases.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, a biotherapeutics company, announced its presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The company will present an abstract titled Domain-Specific Antibodies to Neuropilin 2 Implicate VEGF-C and not Semaphorin 3F in Breast Cancer Stem Cell Function. The poster will be available on the AACR website on the day of the event.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported Q1 2020 results, highlighting significant developments despite COVID-19 disruptions. The company experienced delays in patient enrollment for its Phase 1b/2a trial of ATYR1923 in pulmonary sarcoidosis due to the pandemic. Notably, aTyr secured an $8 million upfront payment from Kyorin for ATYR1923 and raised $20.7 million through a follow-on offering, totaling around $50 million in cash. Furthermore, the FDA accepted an IND for a Phase 2 study of ATYR1923 in severe COVID-19 patients, aiming to evaluate its safety and efficacy.